Axogen prices $124 million stock offering at $31 per share

Axogen Inc. (NASDAQ: AXGN) announced the pricing of an underwritten public offering of 4 million shares of common stock at $31 per share. The peripheral nerve repair technology company expects gross proceeds of approximately $124 million before underwriting discounts and other expenses.

The company has granted underwriters a 30-day option to purchase up to an additional 600,000 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 23, 2026, subject to customary closing conditions.

Wells Fargo Securities and Mizuho serve as lead book-running managers for the offering, with Canaccord Genuity and Raymond James acting as co-managers.

Axogen plans to use net proceeds for early payoff and termination of its term loan facility with Oberland Capital, working capital, capital expenditures and other general corporate purposes.

The offering is being conducted under an automatic shelf registration statement on Form S-3ASR that became effective upon filing with the Securities and Exchange Commission on January 21, 2026.

Axogen develops and markets surgical solutions for peripheral nerve repair, with products including Avance nerve grafts, Axoguard nerve connectors and protectors, and Avive+ soft tissue matrix.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Kairos Pharma announces 1-for-7 reverse stock split
• Werewolf Therapeutics to merge with Ambros in $150M private placement